Schering AG Leukine enters Phase III for Crohn’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG is initiating a Phase III study of its white blood cell stimulator Leukine (sargramostim), the firm announces Aug. 28. The decision follows positive results from a recently completed 124-patient trial in moderately to severely active Crohn's. Results will not be disclosed until journal publication and presentation at medical meetings. Schering AG's U.S. subsidiary Berlex markets Leukine in the oncology market. The firm acquired Leukine from Immunex, which was required to divest the drug in connection with its acquisition by Neupogen manufacturer Amgen...
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.